Last reviewed · How we verify
pioglitazone + simvastatin
This combination reduces blood glucose through insulin sensitization (pioglitazone) and lowers cholesterol by inhibiting HMG-CoA reductase (simvastatin).
This combination reduces blood glucose through insulin sensitization (pioglitazone) and lowers cholesterol by inhibiting HMG-CoA reductase (simvastatin). Used for Type 2 diabetes mellitus with dyslipidemia.
At a glance
| Generic name | pioglitazone + simvastatin |
|---|---|
| Sponsor | University of Leipzig |
| Drug class | Thiazolidinedione + HMG-CoA reductase inhibitor combination |
| Target | PPAR-γ (pioglitazone); HMG-CoA reductase (simvastatin) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Pioglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ), improving insulin sensitivity and reducing hepatic glucose production. Simvastatin is a statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol and cardiovascular risk. Together, they address both glycemic control and lipid management in patients with type 2 diabetes and dyslipidemia.
Approved indications
- Type 2 diabetes mellitus with dyslipidemia
Common side effects
- Fluid retention / edema
- Weight gain
- Myalgia
- Hypoglycemia
- Elevated liver enzymes
Key clinical trials
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Study to Evaluate the Effect of Simvastatin, Losartan and Pioglitazone on Patients With Peripheral Arterial Disease. (EARLY_PHASE1)
- Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers (NA)
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) (PHASE3)
- Pioglitazone in Impaired Glucose Tolerance (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pioglitazone + simvastatin CI brief — competitive landscape report
- pioglitazone + simvastatin updates RSS · CI watch RSS
- University of Leipzig portfolio CI